Abakkus Mutual Fund is strategically allocating 30% to smallcaps within its Flexi Cap Fund, identifying mispriced opportunities despite str...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

Rising crude oil prices are pressuring chemical sector margins due to increased feedstock and energy costs. Despite this, the Nifty Chemica...

Geopolitical tensions, particularly the Iran crisis, are overshadowing strong corporate earnings, according to Dipan Mehta. While India Inc...

Cohance Lifesciences shares dropped significantly after reporting an 84% year-on-year decline in March-quarter net profit. Jefferies downgr...

Market expert Dipan Mehta finds India's current earnings season strong. He notes that future quarters will test corporate India due to pote...

Geopolitical fears are driving crude oil prices higher, but Piper Serica's Abhay Agarwal believes this is a temporary, sentiment-driven spi...

Shares of Cohance Lifesciences surged 20% on Monday after the appointment of former Cipla CEO Umang Vohra as its new Executive Chairman and...

Indian markets present attractive long-term investment opportunities following recent corrections, according to Nitin Raheja of Julius Baer...

STCH is revolutionizing fabric development with AI. The company helps fashion brands design and source materials efficiently. This platform...

Smallcap valuations seem high but underlying fundamentals have improved. Aditya Khemani of Invesco Mutual Fund sees this as a structural sh...

The US has slapped up to 100% tariffs on patented drugs, sparing generics and biosimilars but exposing India’s speciality pharma players. S...

The Indian pharmaceutical sector is poised for growth, driven by government support for R&D and manufacturing. Policies promoting bulk drug...

After the merger becomes effective, all shareholders of Cohance will be issued shares of Suven at the ratio of 11 shares of Suven for every...

Shares of Suven Pharmaceuticals surged 13% on the NSE after proposing a merger with Cohance Lifesciences to strengthen its CDMO industry po...

Suven has been 50% owned by Advent since 2022 acquisition, with the remaining with public and institutional shareholders while Cohance is w...

Promoter of Suven Pharma, Advent International, had said last year that it would merge the two businesses post the buyout of its significan...